...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Modern Pathology >Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype
【24h】

Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype

机译：原发性乳腺弥漫性大B细胞淋巴瘤显示非生殖器中心B细胞表型

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Primary breast diffuse large B-cell lymphoma has a poor prognosis relative to other extranodal diffuse large B-cell lymphoma. Recently, diffuse large B-cell lymphoma has been subclassified as germinal center B-cell-like and nongerminal center B-cell types using tissue microarrays. The 5-year overall survival rate of the germinal center B-cell group is better than that of the nongerminal center B-cell group. To elucidate the reason for which primary breast diffuse large B-cell lymphoma has a poor clinical outcome, we investigated 15 patients with primary breast diffuse large B-cell lymphoma (stage IE; 13 cases, stage IIE; two cases) by immunohistochemistry using various markers including CD10, Bcl-6, MUM1 and MIB-1 and by molecular analysis of the immunoglobulin heavy chain gene variable region. Immunohistochemistry showed 0/15 (positive cases/examined cases) for CD10, 5/15 for Bcl-6, 15/15 for MUM1, 10/15 for Bcl-2, 2/15 for CD5 and 4/15 for CD40. The expression pattern of CD10(-) MUM1(+) in primary breast diffuse large B-cell lymphoma corresponded to the nongerminal center B-cell group. Moreover, the MIB-1 index was distributed from 60 to 95% with a mean of 79%, indicating a high proliferation of the lymphoma cells. The immunoglobulin heavy chain gene variable region of primary breast diffuse large B-cell lymphoma had a mutation frequency of 1–10% (seven cases) and 0–1 additional mutations in ongoing mutation analysis (five cases). Primary breast diffuse large B-cell lymphoma had characteristics of the nongerminal center B-cell group. In conclusion, primary breast diffuse large B-cell lymphoma has a nongerminal center B-cell phenotype and has a high MIB-1 index. These features might therefore be associated with poor prognosis.
机译：相对于其他结外性弥漫性大B细胞淋巴瘤，原发性乳腺弥漫性大B细胞淋巴瘤的预后较差。最近，使用组织微阵列将弥漫性大B细胞淋巴瘤分为生发中心B细胞样和非生殖中心B细胞类型。生发中心B细胞组的5年总生存率优于非生发中心B细胞组。为了阐明原发性乳腺弥漫性大B细胞淋巴瘤临床预后较差的原因，我们采用免疫组织化学方法对15例原发性乳腺弥漫性大B细胞淋巴瘤（IE期;​​ 13例，IIE分期; 2例）进行了调查，采用了多种方法标记包括CD10，Bcl-6，MUM1和MIB-1，并通过分子分析免疫球蛋白重链基因可变区。免疫组织化学显示CD10为0/15（阳性病例/检查病例），Bcl-6为5/15，MUM1为15/15，Bcl-2为10/15，CD5为2/15，CD40为4/15。 CD10（-）MUM1（+）在原发性乳腺弥漫性大B细胞淋巴瘤中的表达模式与非生发中心B细胞组相对应。此外，MIB-1指数分布在60％到95％之间，平均为79％，表明淋巴瘤细胞高度增殖。原发性乳腺弥漫性大B细胞淋巴瘤的免疫球蛋白重链基因可变区的突变频率为1–10％（7例），正在进行的突变分析中有0–1的其他突变（5例）。原发性乳腺弥漫性大B细胞淋巴瘤具有非生殖器中心B细胞组的特征。总之，原发性乳腺弥漫性大B细胞淋巴瘤具有非生殖器中心B细胞表型，并具有较高的MIB-1指数。因此，这些特征可能与不良预后有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号